Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman.
Longitudinal effects of aging on serum total and free testosterone levels in healthy men.
J Clin Endocrinol Metab, 86 (2001), pp. 724-731
[2.]
H.A. Feldman, C. Longcope, C.A. Derby, C.B. Johannes, A.B. Araujo, A.D. Coviello, et al.
Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study.
J Clin Endocrinol Metab, 87 (2002), pp. 589-598
[3.]
J.M. Kaufman, A. Vermeulen.
Declining gonadal function in elderly men.
Bailliere's Clin Endocrinol Metab, 11 (1997), pp. 289-309
[5.]
J.D. Veldhuis.
Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamic-pituitary-gonadal axis.
J Androl, 20 (1999), pp. 1-17
[6.]
J.M. Zmuda, J.A. Cauley, A. Kriska, N.W. Glynn, J.P. Gutai, L.W. Kuller.
Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men.
Amer J Epidemiol, 146 (1997), pp. 609-617
[7.]
A. Gray, H.A. Feldman, J.B. McKinlay, C. Longcope.
Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study.
J Clin Endocrinol Metab, 73 (1991), pp. 1016-1025
[8.]
A. Vermeulen.
Androgen replacement therapy in the aging male. A critical evaluation.
J Clin Endocrinol Metab, 86 (2001), pp. 2380-2390
[9.]
G.B. Phillips, B.H. Pinkernell, T.Y. Jing.
The association of hypotestosteronemia with coronary artery disease in men.
Arterioscl Thromb, 14 (1994), pp. 701-706
[10.]
D. Simon, M.A. Charles, K. Nahoul, G. Orssaud, J. Kremski, V. Hully, et al.
Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study.
J Clin Endocrinol Metab, 82 (1997), pp. 682-685
[11.]
J.J. Corrales, R.M. Burgo, J.M. Miralles, E. Villar.
Abnormalities in sperm acid glycosidases from infertile men with idiopathic oligoasthenoteratozoospermia.
Fertil Steril, 73 (2000), pp. 470-478
[12.]
Corrales JJ. Envejecimiento del sistema endocrino: andropausia. Conferencia en las III Jornadas de la Sociedad Castellano-Manchega de Geriatría y Gerontología, 18 de Octubre de 2002, Talavera de la Reina, Toledo.
[13.]
A.M. Matsumoto.
Andropause: clinical implications of the decline in serum testosterone levels with aging in men.
J Gerontol, 57A (2002), pp. M76-M99
[14.]
S.M. Haffner, R.A. Valdez, L. Mykkänen, M.P. Stern, M.S. Katz.
Decreased testosterone and dehydroepiandrosterone sulphate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men.
Metabolism, 43 (1994), pp. 599-603
[15.]
D. Goodman-Gruen, E. Barrett-Connor.
Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women.
Diabetes Care, 23 (2000), pp. 912-918
[16.]
R.S. Tan, S.J. Pu.
Impact of obesity on hypogonadism in the andropause.
Int J Androl, 25 (2002), pp. 195-201
[17.]
J.E. Morley, E. Charlton, P. Patrick, F.E. Kaiser, P. Cadeau, D. Mc-Cready, et al.
Validation of a screening questionnaire for androgen deficiency in aging males.
Metabolism, 49 (2000), pp. 1239-1242
[18.]
S. Bhasin, C.J. Bagatell, W.J. Bremner, S.R. Plymate, J.L. Tenover, S.G. Korenmann, et al.
Issues in testosterone replacement therapy in older men.
J Clin Endocrinol Metab, 83 (1998), pp. 3435-3448
[19.]
The Second Annual Andropause Consensus Meeting.
[20.]
R.R. Hajjar, F.E. Kaiser, J.E. Morley.
Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis.
J Clin Endocrinol Metab, 82 (1997), pp. 3793-3796
[21.]
R.J. Urban, Y.H. Bodenburg, C. Gilkison, J. Foxworth, A.R. Coggan, R.R. Wolfe, et al.
Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis.
Amer J Physiol (Endocrinol Metab), 32 (1995), pp. E820-E826
[22.]
P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, D.A. Lenrow, et al.
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.
J Clin Endocrinol Metab, 84 (1999), pp. 2647-2653
[23.]
A.M. Kenny, K.M. Prestwood, C.A. Gruman, K.M. Marcello, L.G. Raisz.
Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels.
J Gerontol A Biol Med Sci, 56 (2001), pp. M266-M272
[24.]
P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, J.H. Holmes, et al.
Effect of testosterone treatment on bone mineral density in men over 65 years of age.
J Clin Endocrinol Metab, 84 (1999), pp. 1966-1972
[25.]
S. Zgliczynski, M. Ossowski, J. Slowinska-Srzednicka, A. Brzezinska, W. Zglicznynski, P. Soszynki, et al.
Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.
Atherosclerosis, 121 (1996), pp. 35-43
[26.]
K.M. English, R.P. Steeds, T.H. Jones, M.J. Diver, K.S. Channer.
Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. A randomized, double-blind, placebo-controlled study.
Circulation, 102 (2000), pp. 1906-1911
[27.]
V. Bakhshi, M. Elliott, A. Gentili, M. Godschalk, T. Mulligan.
Testosterone improves rehabilitation outcomes in ill older men.
J Am Geriatr Soc, 48 (2000), pp. 550-553
[28.]
M.T. Haren, J.E. Morley, I.M. Chapman, P.D. O'Loughlin, G.A. Wittert.
Defining “relative” androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health?.
Climacteric, 5 (2002), pp. 15-25
[29.]
P. Kunelius, O. Lukkarinem, M.L. Hannuksela, O. Itkonen, J.S. Tapanainem.
The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.
J Clin Endocrinol Metab, 87 (2002), pp. 1467-1472
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición